Kornimate/medical-research-clean huggingface dataset:
clinical outcomes in pediatric obsessive-compulsive disorder

Conditions: Obsessive-compulsive Disorder

Summary: obsessive-compulsive disorder (ocd) is a common neuropsychiatric illness beginning in childhood. effective ocd treatments include cognitive-behaviour therapy (cbt) and medications but access to treatment is difficult and does not systematically include parents. the investigators will evaluate clinical and neural effects of group-based family cbt (gf-cbt), via a case-control study including: group 1 - ocd cases receiving gf-cbt (n=90); group 2 - ocd waitlist cases (n=90). effects will be measured between baseline and completion of 12 gf-cbt sessions: comparing ocd severity and functioning changes between groups 1 and 2.

effective ocd treatment approaches in children and youth include cognitive-behaviour therapy (cbt) and serotonergic medications; however, the disorder is under-diagnosed and access to care is frequently delayed or difficult to obtain. moreover, despite the important role of family accommodation as an outcome predictor, standard cbt does not systematically include parents and mechanisms of response are not fully understood. the investigators propose to address this challenge by evaluating a novel treatment approach called group-based family cbt (gf-cbt). to determine clinical and neural effects of gf-cbt, we will perform a case-control study of two groups: group 1 - ocd-affected youth receiving gf-cbt treatment (n=90); group 2 - ocd-affected youth receiving no new treatment (waitlist controls; n=90). the investigators will collect clinical outcome data related to ocd severity, individual and family functioning at four time points for group 1 subjects and at two time points for group 2 subjects. for group 1 subjects, these time points include baseline, at midpoint, at the completion of 12 sessions, and at one-month follow-up (all time points are +/- one week). for group 2 subjects, time points will be at baseline and after a time delay equivalent to completion of 12 gf-cbt sessions. clinical measures will be used to compare changes between gf-cbt treatment and waitlist-control groups (groups 1 versus 2).

Eligibility criteria:
inclusion criteria: * male or female, aged 5-18 years old * ability of subject and parent to provide informed assent/consent * english-speaking * current dsm iv-tr axis i diagnosis of childhood-onset ocd; moderate to severe ocd (cy-bocs≥16/40) exclusion criteria: * current diagnosis of bipolar disorder, psychosis, mental retardation or pervasive developmental disorder (e.g., autism), and current or past substance dependence/abuse

Keywords: obsessive-compulsive disorder pediatric group-based cognitive-behavioural therapy
a multicenter study of clinical epidemiology of breast cancer in shaanxi province of china

Conditions: Breast Cancer

Summary: the purpose of the study is to study the epidemic features and diagnosis of female breast cancer, especially the diagnosis and treatment of breast cancer.the disease-free survival (dfs) and the total survival time(os) of the breast cancer patients will also be studied.

the study is a multicentric, retrospective clinical study based on the hospital. the target number of cases are x patients who are eligible for breast cancer after radical mastectomy. to collect the clinicopathological data and treatment data of the breast cancer patients and do the follow-up visit of all the patients who are included in the study.

Eligibility criteria:
inclusion criteria: * female patients; * the hospitalized patients who are confirmed of the primary breast cancer histologically; * the date of the inpatients are within the month we chosen; * patients who are within the month we chosen have been received or under receiving the relevant treatment including surgical treatment, chemotherapy and radiotherapy. exclusion criteria: * male breast cancer patients; * patients with breast cancer who are not under the chosen time; * non hospitalized patients.

Keywords: breast cancer, hospital, epidemiology, diagnosis, treatment
evaluating modulation effects of temporal interference using seeg

Conditions: Deep Brain Stimulation; Drug Resistant Epilepsy

Summary: this single-center prospective study aims to investigate the electrophysiological mechanisms of temporal interference (ti) in humans by analyzing clinical, imaging, and electrophysiological data from patients aged 14-60 with drug-resistant epilepsy.

temporal interference (ti) technology is a novel non-invasive method for deep brain stimulation (dbs). by generating an overlapping electric field from safe currents, ti creates focused stimulation in targeted deep brain areas. this approach allows for the exploration of deep brain nuclei functions and has the potential to serve as a non-invasive alternative to traditional invasive dbs for clinical treatments. stereoelectroencephalography (seeg) is a method for recording electrical activity from deep brain structures using implanted depth electrodes to provide a three-dimensional view of neuronal activity. this study aims to investigate the electrophysiological mechanisms of temporal interference (ti) deep brain stimulation by including patients aged 14-60 with implanted intracranial electrodes. during and after ti stimulation, electrophysiological and clinical data will be recorded. clinical, imaging, and electrophysiological data will be analyzed and processed to advance understanding of ti's effects in deep brain stimulation.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of drug-resistant epilepsy; * no severe systemic diseases; * implantation of stereotactic electrodes; * agreement to participate in this study and signs the informed consent form. exclusion criteria: * hematoma at the scalp electrode site or fluid accumulation under the electrode after intracranial electrode placement.

Keywords: temporal interference stereoelectroencephalography drug resistant epilepsy
intramedullary nailing vs external ring fixation for the treatment of tibial shaft fractures

Conditions: Tibial Shaft Fracture

Summary: this study is a multicenter pragmatic assessor blinded randomized and prospective clinical trial in which standard intramedullary nailing is compared with external ring fixator for patients with tibial shaft fractures.

this study is a multicenter pragmatic assessor blinded randomized and prospective clinical trial in which standard intramedullary nailing is compared with external ring fixator for patients with tibial shaft fractures. the primary aim of the project is to compare the one-year knee injury and osteoarthritis outcome score - sport (koos-sport) after standard intramedullary nailing with external ring fixation for patients with tibial shaft fractures. the explorative aim is to report the effect of the two surgical procedures on the development of complications, time to bone union, pain reactions, muscle strength, activity of daily living and time to return to work.

Eligibility criteria:
inclusion criteria: * fracture of the tibial shaft * ota classification type: 42-a1-a3, -b1-b3 and -c1-c3 * the fracture type is deemed operable by intramedullary nail exclusion criteria: * below 18 years of age * open fracture * history of severe systemic diseases or cancer * bilateral tibial shaft fracture * multi fracture patients * pregnancy * patients without gait function prior to fracture

Keywords: external ring fixation intramedullary nailing tibial shaft fracture patient reported outcome
calcified cerebral embolism: a descriptive study in a large single center cohort

Conditions: Calcified Cerebral Embolism

Summary: calcified cerebral embolism (cce) is a relatively rare but underdiagnosed cause of infarction. cce diagnosis is made by ct. radiological characteristics of cce have been reported in small case series. the aim of this study was to describe clinical and radiological characteristics of cce in a large number of patients, and to compare patients with different radiological cce characteristics.


Eligibility criteria:
inclusion criteria: * patients with cee treated with intravenous thrombolysis (ivt) between 2015 and 2020 managed at the chu de nîmes or patients with tia/stroke with ecc identified on ct between 12/2019 and 04/2023 managed at chu de nîmes exclusion criteria: * patient's refusal to use his/her data

Keywords: calcified cerebral embolism cerebral infarction radiological characteristics
hyaluronic acid and articular pain

Conditions: Osteoarthritis

Summary: this is a prospective longitudinal single-center clinical study on oa patients treated with ha . patients will be enrolled at baseline (t0) and then monitored at 90 days (t1), 180 days (t2; ), and 360 days (t3). the first efficacy end-point will be the statistically significant difference (p\<0.05) in vas scale between t2 and t0 and between t3 and t2

this is a prospective longitudinal single-center clinical study on oa patients treated with ha at the pain medicine room of the clinical pharmacology and pharmacovigilance operative unit of the "renato dulbecco" university hospital of catanzaro from january 2023 to december 2024. patients will be enrolled at baseline (t0) and then monitored at 90 days (t1), 180 days (t2), and 360 days (t3). at the beginning of the study, all enrolled patients signed the informed consent. after the enrollment (t0) and during the follow ups (t1-t3), clinical and laboratory data will be collected directly by the medical staff involved in the study and zung sas, zung sds and sf-36 questionnaires will be administered. the dedicated database evaluated and recorded any systemic or local side effects. ha will be administered at the beginning of the study (t0) in agreement with the leaflet. the first efficacy end-point will be: the statistically significant difference (p\<0.05) in vas scale between t2 and t0 and between t3 and t2 the statistically significant difference (p\<0.05) in functional mobility and walking ability (six minutes walking test) between t2 and t0 and between t3 and t2 the statistically significant difference (p\<0.05) in mood disorders (zung sas and zung sds) between t2 and t0 and between t3 and t2

Eligibility criteria:
inclusion criteria: 1. patients of both sexes between 18 and 65 years old, with a body mass index \< 29 kg/m2. 2. patients with second- or third-degree of oa 3. patients with vas (visual analogue scale) intensities higher than 5/10 who did not respond to systemic medication therapy. 4. patients who can comprehend the study's objectives and (adhere to the orthopedist's instructions, return for follow-up, and complete the evaluation questionnaires). 5. patients able to provide their written informed consent to participate to the study and to use their data anonymously for scientific purposes exclusion criteria: 1. presence of active malignancy of any type or history of malignancy 2. local or systemic infection. 3. uncooperative patient or suffering from neurological disorders, therefore unable to follow the orthopedist's instructions or unable to provide informed consent for participation in the study or who have not provided written consent. 4. any case not described in the inclusion criteria.
an investigational study to evaluate experimental medication bms-986224 in renally impaired participants

Conditions: Cardiac Failure; Myocardial Failure

Summary: the purpose of this study is to investigate the experimental medication bms-986224 in participants with varying levels of renal function.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * bmi ≥18 and ≤ 35kg/m2 * systolic blood pressure \>100 mmhg exclusion criteria: * women of childbearing potential or women who are currently pregnant * clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, ecg, or laboratory tests at screening that the investigator judges as likely to interfere with the objectives of the trial or the safety of the volunteer * current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption other protocol defined inclusion/exclusion criteria could apply
computational imaging research based on deep learning

Conditions: Arterial Aneurysm

Summary: computational imaging research based on deep learning

based on the current technical challenges, subject development and upgrade of knowledge, to avoid the occurrence of adverse medical accidents, simplify the diagnostic process, artificial intelligence has become the alternative method of choice, by constructing training deep learning model, the cta as model inputs aneurysm detection and diagnosis to improve diagnosis effectiveness, promote the development of medical technology

Eligibility criteria:
inclusion criteria: 1. age: 18-80 years. 2. ct paired imaging data of vessels, including layer-to-layer plain ct and enhanced ct. 2 time range: january 2010 to december 2021. 3. scanning sites: ct and cta of head, neck, chest, abdomen or iliac. exclusion criteria: 1. unpaired ct image . 2. severe artifact ct image. 3. enhancement ct failure image (failure to capture arterial phase or poor arterial development, insufficient flow of contrast agent, etc.)

Keywords: arterial aneurysm
tulobuterol patch in pediatric patients undergoing tonsillectomy

Conditions: Tonsillar Hypertrophy

Summary: * tonsillectomy is a common pediatric procedure for the treatment of sleep-disordered breathing and chronic tonsillitis. up to half of children having this procedure experience a perioperative respiratory adverse event. * we tried to determine whether tulobuterol patch (transdermal bronchodilator) premedication decreases the risk of perioperative respiratory adverse events in children undergoing anesthesia for tonsillectomy.


Eligibility criteria:
inclusion criteria: * pediatric patients undergoing tonsillectomy exclusion criteria: * recent upper respiratory infection (2weeks) * allergy to tulobuterol patch * patients receiving catecholamine (epinephrine, isoproterenol) * hyperthyroidism * hypertension * cardiac disease * diabetes melitus * atopic dermatitis * asthma
microscopic peritoneal metastases after complete macroscopic cytoreductive surgery for epithelial ovarian cancer

Conditions: Epithelial Ovarian Cancer

Summary: the objective of the cytoreductive surgery carried out for the management of ovarian cancers is to obtain a complete macroscopic cytoreduction. this means that all visible peritoneal metastases must be resected. the peritoneum is the most frequent site of recurrence after initial management. there is no data on the existence, prevalence of microscopic peritoneal metastases. it nevertheless represents a therapeutic target (intraperitoneal chemotherapy). the main objective is the demonstration of microscopic peritoneal metastases in macroscopically healthy peritoneum after complete macroscopic cytoreductive surgery.

understanding biology and progression mechanisms of peritoneal metastases (pm) of epithelial ovarian cancer (eoc) is a cornerstone in the knowledge and the comprehensive management of the disease, as pm will occur in the majority of patients. indeed, the goal of cytoreductive surgery (crs) in these patients is to completely remove all visible peritoneal invasion because the absence of residual disease after surgery is known to improve the prognosis. despite clinical remission after the completion of complete surgery and platinum-based chemotherapy, 60% of patient develop peritoneal recurrence. this suggests that microscopic lesions may be present that are not eradicated by surgery, not controlled by systemic chemotherapy and that may be one of the mechanisms leading to peritoneal recurrence. peritoneal carcinomatosis is responsible for the greatest morbidity and mortality in women with eoc. there are very few studies in the literature on microscopic peritoneal involvement in eoc, its detection and potential role in the progression of cancer. the peritoneum should be considered an organ in its own right and the surgeon must treat peritoneal metastases with the intent to cure. to follow the recommendations, this microscopic disease must be managed, because complete crs is now a skill that can be mastered skill and its uses is a validated guideline. moreover, "complete crs" should be defined as "without macroscopic residual disease" thus highlighting the presence of microscopic disease. the goal of this study is to add scientific evidence for the existence of microscopic peritoneal metastases (mpm) and to justify the need for additional diagnostic and therapeutic approaches.

Eligibility criteria:
inclusion criteria: * age \> 18 years-old, french nationality * with epithelial ovarian or tubal cancer * complete macroscopic cytoreductive surgery (cc-0) regardless of the sequence compared to chemotherapy. * patient giving express consent exclusion criteria: * borderline ovarian tumor * incomplete cytoreductive surgery * pregnant women * major under guardianship / trusteeship, * not insured

Keywords: ovarian peritoneal recurrences surgery cancer metastases
a phase i study to investigate the effect of hepatic impairment on the pk, safety, and tolerability of azd2693

Conditions: Hepatic Impairment

Summary: subcutaneous administration of azd2693 single dose in participants with hepatic impairment

this is a phase i, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the pk, safety, and tolerability of azd2693 administered as an subcutaneous injection in male and female participants with mild, moderate, or severe hepatic impairment compared with male and female participants with normal hepatic function (as control). eight participants with mild impairment (cp class a); 8 participants with moderate impairment (cp class b); 8 participants with severe impairment (cp class c); and 8 to12 participants with normal hepatic function matched on a group level regarding age, body weight, and sex to the impaired participants are planned for study intervention with the goal of having at least 6 evaluable participants within each group. study participants who self-withdraw after study intervention may be replaced to ensure that at least 6 participants per group are evaluable and complete the study per protocol. an evaluable participant is defined as having adequate plasma pk profile to meet the primary study objective. child-pugh scoring, detailed in table 2, will be used to determine the level of hepatic impairment. participants will be enrolled into the following groups based on their cp classification score as determined at screening: group 1: participants with mild hepatic impairment (cp class a, score of 5 or 6). group 2: participants with moderate hepatic impairment (cp class b, score of 7 to 9). group 3: participants with severe hepatic impairment (cp class c, score of 10 to 15). group 4: participants with normal hepatic function. study arms and duration: * planned screening duration per participant: up to 4 weeks. * planned study duration (screening to follow-up) per participant: up to 16 weeks.

Eligibility criteria:
inclusion criteria: for hepatic: * participant with a diagnosis of chronic and stable hepatic impairment for healthy: * participant with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or 12-lead ecgs, all participants: - body weight ≥ 50 kg; bmi within the range of 18.0 to 40.0 kg/m2 (inclusive) as measured at screening exclusion criteria: * participant with impaired hepatic function has egfr \< 60 ml/minute/1.73 m2 and participant with normal hepatic function has egfr \< 90 ml/minute/1.73 m2 * positive test for hiv at screening * history or presence of clinically significant thyroid disease * history or presence of clinically significant or unstable medical or psychiatric condition * history of any major surgical procedure within 30 days prior to study intervention

Keywords: mild moderate severe healthy matches
validation of the french version rtwse (return to work self efficacy scale)

Conditions: Chronic Low Back Pain

Summary: the back pain connected to the work stay a major problem in industrialized countries, in particular because of the repercussions of this affection on the work (sick leave, absenteeism, handicap and inaptitude). it is difficult to consider among all the patients with a chronic low back pain in the work: how much they are going to stop. however, investigator can consider that approximately 20 % of the patients have a sick leave. several studies showed well that more the sick leave work stoppage goes on more the risk of not resumption of work increases. several risk factors were associated to the evolutionary forecast of the pathology and thus to the extension extra time of the sick leave: individual, environmental, psychosocial and organizational. the evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with low back pain. this parameter also allows highlight other levers of actions in the therapeutic education.

first stage: the translation of the rtwse in french followed the recommendations of the literature, which recommend a double translation, then a double back - translation with synthesis of the data in every stage. a final commission deliberate then a final translation, culturally adapted. the second stage: the rtwse is given to the patients with a chronic back pain in the program of functional restoration of the rachis. questionnaire fabq, barbecue and quebec are also given to the patient to obtain the status "faith" and the "functional" status. the questionnaire jdi as well as the analog visual scale is given to estimate the global professional satisfaction. the pain is estimated by a digital scale. the score ipaq allows to estimate the level of physical activity of the patients. the had allows to estimate the level of anxiety and depression of the patients. the additional questionnaires used for several reasons: in routine for the evaluation of the patients with a chronic back pain; to characterize the patients and within the framework of the study for the validity of convergence and difference of questionnaires rtwse 10 and 19 items. the third stage: the questionnaire rtwse is given again to the patient at 72 hours interval while the state of the patient is considered as stable. the fourth stage: the questionnaires are given at j21 and in 2 months apart for the study of the sensibility in the change with the fabq, barbecue, quebec and the ipaq.

Eligibility criteria:
inclusion criteria: * both sexes * adult (\>18 years old) * chronic low back pain evolving for at least 3 months * acceptance to participate in the study * patients affiliated to a social security scheme (beneficiary entitled) exclusion criteria: * patient under guardianship, or protection of justice. * patient in the incapacity to answer the questionnaire.

Keywords: chronic low back pain function self-efficacy return to work questionnaire